University Of Michigan Ann Arbor

Years of research into chimeric antigen receptor T-cell therapy for cancer treatment is finally paying dividends.

In this exclusive video from the Congress of the European Crohn’s and Colitis Organisation, Peter D.R. Higgins, MD, PhD, director of the IBD program at the University of Michigan, discusses a new patient-reported outcome tool that was developed and used to assess experience and quality of life in patients with ulcerative colitis.

For decades, prognostic markers and therapeutics have been focused largely on the cancer cell’s growth patterns in tissue culture or in animal models.

The prevalence of benzodiazepine use among adults in the United States was higher than previously reported, according to a study analyzing data from the National Survey on Drug Use and Health.

CHICAGO — Among patients with advanced HF designated for left ventricular assist device therapy, mesenchymal precursor cells did not improve cardiac recovery, but there was a signal of benefit in ischemic HF, according to the results of the LVAD MPC-II trial.

An FDA advisory committee panel discussed several topics regarding the clinical evaluation of device-based therapies, including renal denervation for patients with hypertension.

The Prostate Cancer Foundation granted $6 million to 29 early-career scientists through its Young Investigator Awards program.

Opioid prescriptions have steadily decreased since 2012, but after the release of the CDC’s opioid prescribing guideline in 2016, several risky prescribing practices have declined at a significantly faster rate, according to research published in Annals of Internal Medicine.

American Society for Radiation Oncology designated 35 members as ASTRO fellows.

Many years ago, I worked on new and exciting antibiotics that had activity against naturally resistant organisms such as Pseudomonas and Proteus species. Some of these antibiotics were ampicillin, first-generation cephalosporins and tobramycin. We are now in a new ball game of acquired resistance, and for this report, I have turned over the job of describing some of the newer antibiotics to researchers who are in the forefront of antimicrobial resistance. – by Donald Kaye, MD, MACP